Thursday, May 30, 2019
RI MUHC - 1001 Decarie Blvd, Montreal, Quebec H4A 3J1
12:00 - 12:45聽 聽 聽 聽 聽 聽 聽 聽聽 |
Registration & lunch |
Session 1 | Co-Chairs : Michael Gagnon, MD & Guillaume Lepage-Mireault, MD Location: RI MUHC - ES1.1129 - Drs. Sylvia & Richard Cruess Amphitheatre |
12:45 - 1:00 | Opening Remarks Sophie Bernard, MD Director, Lipids, Nutrition and Cardiovascular Prevention Clinic, Montreal Clinical Research Institute (IRCM) Assistant Professor, Department of Medicine, Faculty of Medicine, Universit茅 de Montr茅al |
1:00 - 1:45 |
PCSK9: from Discovery to Therapeutic ApplicationsNabil G. Seidah, PhD, OQ, MRSC, MC |
1:45 - 2:30 |
Clinical Trials of PCSK9 Inhibitors for the Prevention of ASCVDShaun Goodman, MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS |
2:30 - 3:15 |
Canadian Guidelines for the Treatment of DyslipidemiasGeorge Thanassoulis, MD, MSc, FRCP(C) |
3:15 - 3:30 | Break Location: RI MUHC Atrium - ES1 |
Session 2 | Chair: Latifah Alothman, MD Location: RI MUHC - ES1.1129 - Drs. Sylvia & Richard Cruess Amphitheatre |
3:30 - 4:15 |
The Genetics of Familial Hypercholesterolemia (FH)Jean-Baptiste Rivi猫re, PhD聽 |
4:15 - 5:00 |
The Implications of Genetic DiagnosisYann Joly, PhD, FCAHS, Ad.E. |
5:00-5:30 |
Discussion and Public Forum |